**Name of Journal:** *World Journal of Virology*

**Manuscript NO:** 76525

**Manuscript Type:** ORIGINAL ARTICLE

***Basic Study***

**Validity of the patient health questionnaires (phq-2 and phq-9) for screening depression among human immunodeficiency virus patients in Lahore, Pakistan**

Junaid K *et al*. Validity of the patient health questionnaires phq-2 and phq-9

Khunsa Junaid, Iqra Akram, Muhammad Daood, Amjad Khan

**Khunsa Junaid, Muhammad Daood,** Department of Community Medicine, King Edward Medical University, Lahore 54000, Punjab Province, Pakistan

**Iqra Akram,** Department of Pulmonology, General Hospital, Lahore 54000, Punjab Province, Pakistan

**Amjad Khan,** Department of Public Health and Nutrition, the University of Haripur, Haripur 22781, Khyber Pakhtunkhwa, Pakistan

**Author contributions**: All authors contributed to the concept of this study; Junaid K, Akram I conceived the study; Daood M carried out the literature searches; Junaid K distributed the questionnaires and extracted the data; Daood M assessed the study quality; Junaid K and Khan A performed the statistical analysis; Junaid K and Daood M wrote the manuscript; Khan A revised the manuscript; all the authors read the published version of the manuscript and gave their consent.

**Corresponding author:** Khunsa Junaid, Post-graduate trainee, Department of Community Medicine, King Edward Medical University, Lahore 54000, Punjab Province, Pakistan. khunsajunaidmir@gmail.com

**Received:** March 20, 2022

**Revised:** May 6, 2022

**Accepted:** August 26, 2022

**Published online:** September 25, 2022

**Abstract**

BACKGROUND

Many human immunodeficiency virus (HIV) infected patients suffer from depression, but a little focus is given to detecting and treating depression in primary health care. Detection of depression can be improved by introducing short, reliable, and valid screening instruments.

AIM

To determine the psychometric properties of the patient health questionnaire-2 (PHQ-2) and patient health questionnaire-9 (PHQ-9) for depression screening and diagnosis, and the sensitivity and specificity of the PHQ-2 in HIV infected patients.

METHODS

A cross-sectional study was conducted on 158 HIV-infected patients aged 18 years and above in Lahore, Pakistan. PHQ-2 was implemented to screen depression. PHQ-9 was implemented to diagnose major depressive disorder as a reference standard. Reliability, Validity tests and receiver operating characteristic curve were computed.

RESULTS

The Cronbach's alpha of PHQ-2 and PHQ-9 were 0.732 and 0.759, respectively. The study results showed that the score of 2 on PHQ-2 indicates the highest Youden's index of 0.924, with both sensitivity and specificity of 0.96, and the area under the curve for PHQ-2 was 0.98 (95%CI: 0.953-0.998).

CONCLUSION

Good psychometric properties for the PHQ-2 and PHQ-9 indicated their significant potential as tools for depression screening and diagnosis in the HIV-infected population.

**Key Words:** Depression; Validity; Patient health questionnaire-9; Patient health questionnaire-2; HIV/AIDS; Lahore; Pakistan

**©The** **Author(s) 2022.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation**: Junaid K, Akram I, Daood M, Khan A. Validity of the patient health questionnaires (phq-2 and phq-9) for screening depression among human immunodeficiency virus patients in Lahore, Pakistan. *World J Virol* 2022; 11(5): 341-351

**URL**: https://www.wjgnet.com/2220-3249/full/v11/i5/341.htm

**DOI**: https://dx.doi.org/10.5501/wjv.v11.i5.341

**Core Tip:** Many human immunodeficiency virus patients suffer from depression, but a little focus is given to detecting and treating depression in primary healthcare settings. The study aims to assess the psychometric properties of the patient health questionnaire-2 (PHQ-2) and Patient health questionnaire-9 for depression screening and diagnosis and estimate the sensitivity and specificity of the PHQ-2 for depression screening in human immunodeficiency virus infected patients. The study results showed that the score of 2 on PHQ-2 indicates the highest Youden's index of 0.924, with both sensitivity and specificity of 0.96, and the area under the curve for PHQ-2 was 0.98.

**INTRODUCTION**

People living with human immunodeficiency virus (HIV) infection (PLWHA) seem to be more vulnerable to psychiatric morbidity than the overall population[1,2], with major depressive disorder seems to be the most prevalent psychiatric diagnosis. Suicidal thinking, anxiety, post-traumatic stress disorder, and drug/alcohol use disorders are also frequently documented psychiatric morbidities in HIV patients[3,4]. Around 3.8 percent of the world's population suffers from depression, including 5.0 percent of adults and 5.7 percent of people over 60. Depression affects around 280 million people worldwide[5]. The global HIV/AIDS 2020 research estimated that 37.7 million people were infected with HIV infection. Sub-Saharan Africa was linked to about two-thirds of the world's HIV-positive individuals[6]. In Pakistan, an estimated 183705 people infected with HIV by 2020[7]. Even though the expected prevalence of HIV infection in Pakistan's general population is less than 0.1 percent in 2019, it remains a major public health issue[8].

Depression is a mental health condition defined by a depressed mood, low mood, difficulty concentrating, self-blame or poor self-worth, sleeping or eating difficulties, and impaired focus[9-11]. Depression is associated with several clinical and socio-demographic factors in HIV patients. Some clinical factors, such as AIDS-related stigma, compromised immune status (low CD4 counts), and opportunistic infections[12,13] could be distinctive to HIV patients; however, socio-demographic factors such as gender, low levels of education, and unemployment were linked to depression including both HIV positive and negative populations[14]. Untreated depression causes rapid HIV infection advancement and increases deaths[15]. Inflammatory pathway indicators, such as monocytes and pro-inflammatory cytokines, are recognized as contributing to the higher prevalence of depression in HIV-positive individuals[16]. When a person has HIV infection, their body releases more of the pro-inflammatory cytokines interleukin-6 and tumour necrosis factor. These cytokines promote the spread of viruses and the depletion of CD4 cells[17].

Antidepressants were the most frequently recommended drugs, followed by anxiolytics, antipsychotics and psycho-stimulants[18]. Non-invasive brain stimulation (NIBS) techniques such as repeated trans-cranial magnetic stimulation and trans-cranial direct current stimulation are increasingly being used to improve cognitive function and reduce depressive symptoms in a variety of settings[19]. Given that severe depression is typically associated with cognitive impairments, the NIBS method may be beneficial in enhancing cognition in depressed people[20]. More than half of the patients with a serious depressive illness did not use antidepressants. Effective depression treatment may be crucial for increasing HIV medication adherence and clinical outcomes, possibly in combination with adherence supports[21].

Despite successful pharmacological and psychological treatments, a high proportion of individuals suffering from depression in HIV-infected patients is frequently undiagnosed clinically and is frequently untreated in primary health care settings[22,23]. Several screening questionnaires have been developed as instruments to assist in the timely identification of depression and clinical judgment[24-28]. To generate accurate clinical results, the validity and reliability of the depression screening tools should be good. Screening tools should be easy and quick for successful practical application[29-31]. The Patient Health Questionnaire [patient health questionnaire-2 (PHQ-2) and patient health questionnaire-9 (PHQ-9)] were designed especially as depression screening and diagnostic tools for primary care settings to promote the delivery of evidence-based psychiatric care intervention strategies in regions where specially trained mental health providers are scant[32-34].

A cross-culturally applicable form of PHQ-9 and PHQ-2 is available, but its psychometric properties are still to be validated formally. In many studies, the accuracy of PHQ-9 has been tested by applying it to many chronic disease populations[35-40]. However, the PHQ-9 and PHQ-2 have not yet been validated in HIV patients in Pakistan. Therefore, the present study aimed to measure the (1) psychometric properties of the PHQ-9 and PHQ-2 for the diagnosis of depression; and (2) to estimate PHQ-2 screening accuracy by using PHQ-9 as the reference standard in patients of HIV infection in Lahore, Pakistan.

**MATERIALS AND METHODS**

***Study setting***

The study was carried out in the HIV clinic of Jinnah hospital Lahore, Pakistan, from January 2019 to March 2019. HIV clinic in Jinnah hospital Lahore works from Monday to Saturday and serves around 20 to 30 patients per day. The population of Lahore is 11126285, and it is one of the most populated cities in Punjab Province[41]. The current study comprises finding active cases of depression by the use of PHQ-2 for screening, followed by the use of PHQ-9 to detect depression. Patients with a PHQ-9 score of nine or higher were referred to a psychiatrist to confirm the diagnosis of depression.

***Study design***

An analytical cross-sectional study design was executed to assess the validity and reliability of the Patient Health Questionnaire among HIV patients.

***Participants***

One hundred and fifty-eight study participants were recruited from the HIV clinic of Jinnah hospital, Lahore, through a non-probability convenience sampling technique. All participants were agreed to participate in the study. Eligibility criteria for study subjects included age more than 18 years, capability to correspond, understand Urdu language, patients must have a diagnosis of HIV based on positive test on an ELISA for HIV anti-bodies, were attending the HIV clinic for medical care, and were available for a 20 min interview. Participants who had other medical disorders unrelated to HIV, such as renal failure, chronic hepatitis, and malignancy determined on history and clinical examination, were excluded.

***Measures***

**PHQ-9:** It is a nine-component criterion-based diagnostic instrument for the evaluation of depression that identifies the presence and frequency of nine major symptoms of depression in the participant (as recommended by DSM-IV) for two weeks. PHQ-9 is applied frequently in the western world and in sub-Saharan Africa[35,40]. Scoring varies from 0 to 27, and the patient who scores ten or more on PHQ-9 is said to be suffering from depression and should be treated for it to avoid severe consequences. Studies provide evidence that PHQ-9 is designed for self-administration, but it gives the same outcomes when the researcher takes interviews based on this questionnaire[42].

**PHQ-2:** It comprises the first two PHQ-9 questions and evaluates the frequency of past two week’s spells of despair, boredom, and happiness. Questions are valued from 0-3 (4-point scale), where zero represents the complete absence of symptoms and three shows symptoms of depression on each day of the last two weeks with a total score ranging from zero to six[43]. A cutoff value of 3 or more indicates the presence of depression and is associated with a high level of sensitivity and specificity for screening depression[40]. It is easy to use and can be easily applied by healthcare staff of over-burdened health facilities.

**Data collection and study procedures:** Prior to the start of data collection, study participants were informed about the study's objective, and verbal informed consent was obtained. The researcher did a face-to-face interview with the PHQ-2 depression screening questionnaire after receiving informed consent. To obtain socio-demographic information, the clinic file of the patient was examined. Due to the study population's poor literacy level, the survey was administered by the interviewer, and responses were written down. After the screening interview, participants answered the PHQ-9 questionnaire with a second research staff member who was blind to the PHQ-2 results. The interview was conducted by local health care practitioners who had been trained in the use of the PHQ-9 questionnaire. The PHQ-9 was given in the same language as the screening interview, with the help of an interpreter if needed. A good sample size of 200 was chosen due to the restricted availability of staff who can diagnose depression. 158 (79%) of the study participants completed the interview. PHQ-2 items were used to calculate total depression screening scores, and the PHQ-9 items were used to calculate total depression diagnosis scores. Patients with a PHQ-9 score of 9 or above are referred to a psychiatrist to confirm the diagnosis of depression.

**Ethical considerations:** Ethical approval was obtained from the research ethical review board of the Jinnah hospital Lahore, Pakistan. Before the data collection, informed verbal consent was obtained from each study participant.

**HI**

***Statistical analysis***

IBM SPSS version 24 software (Chicago, IL, United States) and the statistical software MedCalc were used to analyze the data. To describe the sociodemographic characteristics of the study participants, descriptive statistics were used. The mean (standard deviation [SD]) was employed to represent continuous data, and the two-sample *t*-test was applied to compare groups. Where applicable, categorical data were evaluated using Pearson's *χ*2 test.The overall Cronbach's alpha coefficient was used to assess the internal consistency of PHQ-2 and PHQ-9. Cronbach's alpha was also calculated with each item removed. The criterion validity of PHQ-2 was determined using receiver operating characteristic (ROC) analysis. Using the PHQ-9 as the reference standard, we employed MedCalc 14.8 to evaluate the sensitivity, specificity, and positive and negative predictive values of the PHQ-2 as a screening tool. Statistical significance was evaluated for all tests using a *P* value of 0.05. The area under the curve (AUC) determines the performance of a test, and an AUC of 0.5 indicates a non-discriminating test. In contrast, the value of AUC of 1.0 specifies perfect diagnostic accuracy. In sensitivity analyses, cutoffs scores balancing sensitivity and specificity were found out utilizing the point of convergence between sensitivity and specificity and Youden's index, which was calculated by (sensitivity + specificity– 1)[44,45].

**RESULTS**

***Participant characteristics***

In total, 158 study participants were completed the PHQ-2 and PHQ-9. The background characteristics of the study participants are mentioned in Table 1. According to the study results, study participants ranged from 18 to 54 years with a mean age of 30.42 ± 7.11 years (± SD). One hundred and thirty-five study participants (85.4%) were male, while twenty-three (14.5%) were female. The total score of PHQ-9 ranged from 0 to 22, with the mean PHQ-9 score being 9.92 (SD = 4.648). By the present study result, PHQ-9 scores were higher in depressed individuals (mean = 12.81) compared to those without depression (mean = 8.41). In most socio-demographic characteristics, no statistically significant differences were found as evaluated by chi-square and *t*-test for gender, education, residence, and religion by depression. However, age, marital status, and monthly family income of HIV patients showed a statistically significant difference with the depression (*P* < 0.05).

***Reliability and item analysis of PHQ-2 and PHQ-9***

The reliability coefficient, Cronbach's alpha for PHQ-9 total score was 0.759, indicating a strong internal consistency. The bivariate correlation between nine items of the PHQ-9 was shown in Table 2, with co-efficient ranging from 0.559 to 0.301, and all correlations were statistically significant (all 2-tailed *P* values < 0.01). Thoughts that harming yourself or dying would be better and moving and feeling bad about yourself or that you are a failure were the two most frequently endorsed items. On the contrary, Feeling down, depressed, or hopeless was the item least frequently endorsed by HIV patients (Table 2). The PHQ-2 had a Cronbach's alpha of 0.732, indicating that the items of the PHQ-2 were consistent. The corrected inter-total correlation was 0.574 and 0.574, respectively.

***Sensitivity and specificity for PHQ-2***

Table 3 showed the sensitivity, specificity, predictive values, and Youden's index at different cutoff scores of the PHQ-2 for depression screening. The study results showed that the score of 2 on PHQ-2 indicates the highest Youden's index of 0.924, with a sensitivity and specificity of 0.96. The area under the curve for PHQ-2 was 0.98 (95%CI: 0.953-0.998) (Figure 1), which indicates excellent criterion validity of PHQ-2 in distinguishing between HIV/AIDS patients with and without major depression with a PHQ-9 diagnosis of depression. The optimum cutoff for detecting depression was found to be a PHQ-2 score of 2, according to study (Table 3).

***Comparison of internal consistency between PHQ-9 and PHQ-2***

According to the present study results, Cronbach's alpha was similar but quite greater for PHQ-9 than in PHQ-2. In ROC curve analysis, The AUC (0.98) was in PHQ-2. The score of 2 on PHQ-2 indicates the highest Youden's index of 0.924, with a sensitivity and specificity of 0.96. When the score of 2 for PHQ2 was assumed, 35.5% of study subjects were diagnosed with probable depression.

**DISCUSSION**

***Key findings***

The current study concludes that PHQ-9 and PHQ-2 are useful tools for detecting depression in people affected by HIV living in Lahore, Pakistan. Cronbach's alpha was similar but quite greater for PHQ-9 than in PHQ-2. In ROC curve analysis, The AUC (0.98) was in PHQ-2. The score of 2 on PHQ-2 indicates the highest Youden's index of 0.924, with a sensitivity and specificity of 0.96.

***Validity and reliability of PHQ-2 and PHQ-9***

Based on analysis of indicators like Youden’s index, sensitivity, specificity, and AUC, a cutoff score of 2 for PHQ-2 was suggested. Anyhow there are a small number of studies assessing the cutoff of depression based on its severity categories[45,46].However, there is highly recommended to determine the cutoff scores of depression based on severity categories amid different populations[47,48]. According to the best of our knowledge, this is the first-ever study on validation and calibration of PHQ-2in the Lahore, Pakistan. Patel *et al*[15] suggested that the best cutoff score was designed by considering the best balance between sensitivity and PPV and is required for its suitability to person-based location and use. Such an instrument is especially significant for routine application in developing regions where healthcare staff is over-burdened.

The current research showed a cutoff score of 2 while using PHQ-2, sensitivity and specificity were 0.96, but this result was different from already done studies[49-51]. A score of 2 is suggested to suspect a patient is suffering from depression in patients of HIV infection when using the PHQ-2 questionnaire based on current and previous studies. The sensitivity value of our study for PHQ-2 is found to be lower than previous studies when a cutoff value of 3 or more is employed along with a documented reference standard. This result can be clarified because we used a sample of patients enrolled consecutively or by chance. One limitation is the design of the study, which is cross-sectional. For acquiring the required sensitivity, we need longitudinal studies. Enrollment of recently diagnosed HIV patients in our study can make the study prone to bias by increasing the estimation of detection of depression with precision[52].

The internal consistency or alpha coefficient for PHQ-9 was 0.759. The value of Cronbach’s alpha must be at least 0.70 or higher for a self-administered questionnaire to be reliable[53,54]. The value of the alpha coefficient of PHQ-9 for our study was lesser than previous studies, where its value was 0.79-0.89, respectively[55,56]. As far as Cronbach’s alpha of PHQ-2 is concerned, it is found to be 0.73, which is remarkably good. This value is also in line with the studies done in various populations[49,57].

***Prevalence of depression***

PHQ-2 outcomes showed the frequency of depression to be 35%. This value is higher when compared with previous studies which also used PHQ-2[48]. This high prevalence of depression in our study participants is consistent across various measures in the results of both instruments, and this concludes that the prevalence of depression in HIV patients in Pakistan can be remarkably higher than the previous estimate. Hence validation with a reliable diagnostic instrument is required to detect the real prevalence of depression[58]. As already discussed in different studies, it is suggested that the first two questions of PHQ-9 may not be able to detect symptoms of depression experienced by HIV patients accurately. It reveals that a remarkable number of HIV patients could not be detected without employing a full PHQ-9 instrument. So it is recommended that PHQ-2 be used for the initial evaluation of patients, but we cannot reach a true conclusion without applying PHQ-9[58].

***Strengths and limitations of the study***

It was the first-ever research done to evaluate the diagnostic accuracy of PHQ-2 for screening major and minor depression in HIV patients by using PHQ-9 as a reference standard. We used a standard instrument that is smaller than other analytical instruments to recognize patients with depression, and it is crucial in primary healthcare settings. PHQ-9 has remarkable properties for the detection of depression and has good capability for assessing the severity of depression.

Especially for evaluation of severity, the PHQ-9 and PHQ-2 offers locally adapted thresholds and follows suggestions to adjust the tool to the background and location when it is intended for application. Because of its shortness, simplicity, and ease of application and interpretation, the use of this instrument is continuously increasing in epidemiological research.

There are a few limitations or constraints in our research. The data were obtained from only one clinic, and hence results cannot be generalized to the population. Because of some reasons, we could not perform test-retest reliability in participants. The study used the cross-sectional design the study, and because of this, we could not establish causation between variables used in our research. Another drawback of this study was that information on participants' mental and physical disabilities was not gathered.

Second, we evaluated the PHQ-2's sensitivity and specificity as a depression screening tool using the PHQ-9 as the reference standard. Therefore, a study utilizing a different diagnostic tool than the PHQ-9 is recommended if the sensitivity or specificity of the PHQ-9 is insufficient as it may bias our estimates of the sensitivity and specificity of the PHQ-2. We propose modifying the PHQ-9 to the local context and literacy level of the population because several participants misunderstood a number of the PHQ-9 items.

**CONCLUSION**

HIV patients are more likely than the general population to develop depression. The PHQ-2 and PHQ-9 showed good psychometric properties, implying that they could be useful as depression screening tools. Due to the substantial health and social burden of depression and need for relatively short, organized, reliable, and valid tools to help healthcare professionals evaluate patients for depression, the PHQ-2 and PHQ-9 would be useful and valuable tools for screening and diagnosing depression in HIV-infected individuals. Moreover, to lessen the global prevalence of psychiatric disorders and improve patient well-being, the instruments can be used in combination with increased access to adequate mental healthcare and therapeutical and non-pharmacological treatments, which are effective in these settings.

**ARTICLE HIGHLIGHTS**

***Research background***

People living with human immunodeficiency virus (HIV) infection (PLWHA) seem to be more vulnerable to psychiatric morbidity than the overall population, with major depressive disorder seems to be the most prevalent psychiatric diagnosis. Suicidal thinking, anxiety, post-traumatic stress disorder, and drug/alcohol use disorders are also frequently documented psychiatric morbidities in HIV patients

***Research motivation***

Many HIV-infected patients suffer from depression, but a little focus is given to detecting and treating depression in primary health care. Detection of depression can be improved by introducing short, reliable, and valid screening instruments.

***Research objectives***

The current study assessed the psychometric properties of the patient health questionnaire-2 (PHQ-2) and patient health questionnaire-9 (PHQ-9) for depression screening and diagnosis and estimated the sensitivity and specificity of the PHQ-2 for depression screening in HIV-infected patients.

***Research methods***

A cross-sectional study was conducted on 158 HIV-infected patients aged 18 years and above in Lahore, Pakistan. PHQ-2 was implemented to screen depression. PHQ-9 was implemented to diagnose major depressive disorder as a reference standard. Reliability, Validity tests and receiver operating characteristic curve were computed.

***Research conclusions***

Due to the substantial health and social liability of depression and need for brief, organized, reliable, and valid tools that can help medical practitioners better assess patients for depression, the PHQ-2 and PHQ-9 would indeed be useful and beneficial instruments for screening and diagnosing depression in HIV-infected persons. Moreover, to lessen the global prevalence of psychiatric disorders and improve patient well-being, the instruments can be used in combination with increased access to adequate mental healthcare and therapeutical and non-pharmacological treatments, which are effective in these settings

***Research results***

The Cronbach's alpha of PHQ-2 and PHQ-9 were 0.732 and 0.759, respectively. The study results showed that the score of 2 on PHQ-2 indicates the highest Youden's index of 0.924, with both sensitivity and specificity of 0.96, and the area under the curve for PHQ-2 was 0.98 (95%CI: 0.953-0.998).

***Research perspectives***

HIV patients are more likely than the general population to develop depression. The PHQ-2 and PHQ-9 demonstrated good psychometric properties, implying that they might be helpful as depression screening tools.

**ACKNOWLEDGEMENTS**

The authors would like to thank all the participants for their cooperation.

**REFERENCES**

1 **Nanni MG**, Caruso R, Mitchell AJ, Meggiolaro E, Grassi L. Depression in HIV infected patients: a review. *Curr Psychiatry Rep* 2015; **17**: 530 [PMID: 25413636 DOI: 10.1007/s11920-014-0530-4]

2 **Remien RH**, Stirratt MJ, Nguyen N, Robbins RN, Pala AN, Mellins CA. Mental health and HIV/AIDS: the need for an integrated response. *AIDS* 2019; **33**: 1411-1420 [PMID: 30950883 DOI: 10.1097/QAD.0000000000002227]

3 **Parcesepe AM**, Bernard C, Agler R, Ross J, Yotebieng M, Bass J, Kwobah E, Adedimeji A, Goulet J, Althoff KN. Mental health and HIV: research priorities related to the implementation and scale up of 'treat all' in sub-Saharan Africa. *J Virus Erad* 2018; **4**: 16-25 [PMID: 30515310]

4 **Wittchen HU**, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jönsson B, Olesen J, Allgulander C, Alonso J, Faravelli C, Fratiglioni L, Jennum P, Lieb R, Maercker A, van Os J, Preisig M, Salvador-Carulla L, Simon R, Steinhausen HC. The size and burden of mental disorders and other disorders of the brain in Europe 2010. *Eur Neuropsychopharmacol* 2011; **21**: 655-679 [PMID: 21896369 DOI: 10.1016/j.euroneuro.2011.07.018]

5 **World Health Organization**. Depression: a global public health concern. [Cited 6 June 2021]. Available from: Available from: http:// www.who.int/mental\_health/management/depression/en/

6 **Joint United Nations Programme on HIV/AIDS**. AIDS by the numbers. [Cited 26 April 2022]. Available from: Available from: https://www.unaids.org/en

7 **Joint United Nations Programme on HIV/AIDS**. “We must ensure that HIV treatment adherence is not compromised”—keeping people in Pakistan on HIV treatment. [Cited 26 April 2022]. Available from: https://www.unaids.org/en/keywords/pakistan

8 **Ahmed A**, Hashmi FK, Khan GM. HIV outbreaks in Pakistan. *Lancet HIV* 2019; **6**: e418 [PMID: 31204244 DOI: 10.1016/S2352-3018(19)30179-1]

9 **Rotenstein LS**, Ramos MA, Torre M, Segal JB, Peluso MJ, Guille C, Sen S, Mata DA. Prevalence of Depression, Depressive Symptoms, and Suicidal Ideation Among Medical Students: A Systematic Review and Meta-Analysis. *JAMA* 2016; **316**: 2214-2236 [PMID: 27923088 DOI: 10.1001/jama.2016.17324]

10 **Demyttenaere K**, Bruffaerts R, Posada-Villa J, Gasquet I, Kovess V, Lepine JP, Angermeyer MC, Bernert S, de Girolamo G, Morosini P, Polidori G, Kikkawa T, Kawakami N, Ono Y, Takeshima T, Uda H, Karam EG, Fayyad JA, Karam AN, Mneimneh ZN, Medina-Mora ME, Borges G, Lara C, de Graaf R, Ormel J, Gureje O, Shen Y, Huang Y, Zhang M, Alonso J, Haro JM, Vilagut G, Bromet EJ, Gluzman S, Webb C, Kessler RC, Merikangas KR, Anthony JC, Von Korff MR, Wang PS, Brugha TS, Aguilar-Gaxiola S, Lee S, Heeringa S, Pennell BE, Zaslavsky AM, Ustun TB, Chatterji S; WHO World Mental Health Survey Consortium. Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys. *JAMA* 2004; **291**: 2581-2590 [PMID: 15173149 DOI: 10.1001/jama.291.21.2581]

11 **Kohn R**, Levav I, de Almeida JM, Vicente B, Andrade L, Caraveo-Anduaga JJ, Saxena S, Saraceno B. [Mental disorders in Latin America and the Caribbean: a public health priority]. *Rev Panam Salud Publica* 2005; **18**: 229-240 [PMID: 16354419 DOI: 10.1590/s1020-49892005000900002]

12 **Antelman G**, Kaaya S, Wei R, Mbwambo J, Msamanga GI, Fawzi WW, Fawzi MC. Depressive symptoms increase risk of HIV disease progression and mortality among women in Tanzania. *J Acquir Immune Defic Syndr* 2007; **44**: 470-477 [PMID: 17179766 DOI: 10.1097/QAI.0b013e31802f1318]

13 **Liu H**, Zhao M, Ren J, Qi X, Sun H, Qu L, Yan C, Zheng T, Wu Q, Cui Y. Identifying factors associated with depression among men living with HIV/AIDS and undergoing antiretroviral therapy: a cross-sectional study in Heilongjiang, China. *Health Qual Life Outcomes* 2018; **16**: 190 [PMID: 30231885 DOI: 10.1186/s12955-018-1020-x]

14 **Rosengren A**, Hawken S, Ounpuu S, Sliwa K, Zubaid M, Almahmeed WA, Blackett KN, Sitthi-amorn C, Sato H, Yusuf S; INTERHEART investigators. Association of psychosocial risk factors with risk of acute myocardial infarction in 11119 cases and 13648 controls from 52 countries (the INTERHEART study): case-control study. *Lancet* 2004; **364**: 953-962 [PMID: 15364186 DOI: 10.1016/S0140-6736(04)17019-0]

15 **Patel V**, Araya R, Bolton P. Treating depression in the developing world. *Trop Med Int Health* 2004; **9**: 539-541 [PMID: 15117296 DOI: 10.1111/j.1365-3156.2004.01243.x]

16 **Norcini Pala A**, Steca P, Bagrodia R, Helpman L, Colangeli V, Viale P, Wainberg ML. Subtypes of depressive symptoms and inflammatory biomarkers: An exploratory study on a sample of HIV-positive patients. *Brain Behav Immun* 2016; **56**: 105-113 [PMID: 26883521 DOI: 10.1016/j.bbi.2016.02.013]

17 **Musinguzi K**, Obuku A, Nakasujja N, Birabwa H, Nakku J, Levin J, Kinyanda E. Association between major depressive disorder and pro-inflammatory cytokines and acute phase proteins among HIV-1 positive patients in Uganda. *BMC Immunol* 2018; **19**: 1 [PMID: 29298663 DOI: 10.1186/s12865-017-0239-3]

18 **Gokhale RH**, Weiser J, Sullivan PS, Luo Q, Shu F, Bradley H. Depression Prevalence, Antidepressant Treatment Status, and Association with Sustained HIV Viral Suppression Among Adults Living with HIV in Care in the United States, 2009-2014. *AIDS Behav* 2019; **23**: 3452-3459 [PMID: 31367965 DOI: 10.1007/s10461-019-02613-6]

19 **Begemann MJ**, Brand BA, Ćurčić-Blake B, Aleman A, Sommer IE. Efficacy of non-invasive brain stimulation on cognitive functioning in brain disorders: a meta-analysis. *Psychol Med* 2020; **50**: 2465-2486 [PMID: 33070785 DOI: 10.1017/S0033291720003670]

20 **Liu S**, Sheng J, Li B, Zhang X. Recent Advances in Non-invasive Brain Stimulation for Major Depressive Disorder. *Front Hum Neurosci* 2017; **11**: 526 [PMID: 29163106 DOI: 10.3389/fnhum.2017.00526]

21 **Ormel J**, Petukhova M, Chatterji S, Aguilar-Gaxiola S, Alonso J, Angermeyer MC, Bromet EJ, Burger H, Demyttenaere K, de Girolamo G, Haro JM, Hwang I, Karam E, Kawakami N, Lépine JP, Medina-Mora ME, Posada-Villa J, Sampson N, Scott K, Ustün TB, Von Korff M, Williams DR, Zhang M, Kessler RC. Disability and treatment of specific mental and physical disorders across the world. *Br J Psychiatry* 2008; **192**: 368-375 [PMID: 18450663 DOI: 10.1192/bjp.bp.107.039107]

22 **Mogga S**, Prince M, Alem A, Kebede D, Stewart R, Glozier N, Hotopf M. Outcome of major depression in Ethiopia: population-based study. *Br J Psychiatry* 2006; **189**: 241-246 [PMID: 16946359 DOI: 10.1192/bjp.bp.105.013417]

23 **Gureje O**, Kola L, Afolabi E. Epidemiology of major depressive disorder in elderly Nigerians in the Ibadan Study of Ageing: a community-based survey. *Lancet* 2007; **370**: 957-964 [PMID: 17869636 DOI: 10.1016/S0140-6736(07)61446-9]

24 **Hughes J**, Jelsma J, Maclean E, Darder M, Tinise X. The health-related quality of life of people living with HIV/AIDS. *Disabil Rehabil* 2004; **26**: 371-376 [PMID: 15204489 DOI: 10.1080/09638280410001662932]

25 **Smit J**, Myer L, Middelkoop K, Seedat S, Wood R, Bekker LG, Stein DJ. Mental health and sexual risk behaviours in a South African township: a community-based cross-sectional study. *Public Health* 2006; **120**: 534-542 [PMID: 16684549 DOI: 10.1016/j.puhe.2006.01.009]

26 **Mokkink LB**, Terwee CB, Patrick DL, Alonso J, Stratford PW, Knol DL, Bouter LM, de Vet HC. The COSMIN study reached international consensus on taxonomy, terminology, and definitions of measurement properties for health-related patient-reported outcomes. *J Clin Epidemiol* 2010; **63**: 737-745 [PMID: 20494804 DOI: 10.1016/j.jclinepi.2010.02.006]

27 **Gilbody S**, Richards D, Brealey S, Hewitt C. Screening for depression in medical settings with the Patient Health Questionnaire (PHQ): a diagnostic meta-analysis. *J Gen Intern Med* 2007; **22**: 1596-1602 [PMID: 17874169 DOI: 10.1007/s11606-007-0333-y]

28 **Kroenke K**, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. *J Gen Intern Med* 2001; **16**: 606-613 [PMID: 11556941 DOI: 10.1046/j.1525-1497.2001.016009606.x]

29 **Pence BW**, Gaynes BN, Atashili J, O'Donnell JK, Tayong G, Kats D, Whetten R, Whetten K, Njamnshi AK, Ndumbe PM. Validity of an interviewer-administered patient health questionnaire-9 to screen for depression in HIV-infected patients in Cameroon. *J Affect Disord* 2012; **143**: 208-213 [PMID: 22840467 DOI: 10.1016/j.jad.2012.05.056]

30 **Kroenke K**, Spitzer RL, Williams JB, Monahan PO, Löwe B. Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection. *Ann Intern Med* 2007; **146**: 317-325 [PMID: 17339617 DOI: 10.7326/0003-4819-146-5-200703060-00004]

31 **Manea L**, Gilbody S, McMillan D. A diagnostic meta-analysis of the Patient Health Questionnaire-9 (PHQ-9) algorithm scoring method as a screen for depression. *Gen Hosp Psychiatry* 2015; **37**: 67-75 [PMID: 25439733 DOI: 10.1016/j.genhosppsych.2014.09.009]

32 **Kiely KM**, Butterworth P. Validation of four measures of mental health against depression and generalized anxiety in a community based sample. *Psychiatry Res* 2015; **225**: 291-298 [PMID: 25578983 DOI: 10.1016/j.psychres.2014.12.023]

33 **Zimmerman M**, Martinez JH, Friedman M, Boerescu DA, Attiullah N, Toba C. Speaking a more consistent language when discussing severe depression: a calibration study of 3 self-report measures of depressive symptoms. *J Clin Psychiatry* 2014; **75**: 141-146 [PMID: 24345406 DOI: 10.4088/JCP.13m08458]

34 **Arroll B**, Goodyear-Smith F, Crengle S, Gunn J, Kerse N, Fishman T, Falloon K, Hatcher S. Validation of PHQ-2 and PHQ-9 to screen for major depression in the primary care population. *Ann Fam Med* 2010; **8**: 348-353 [PMID: 20644190 DOI: 10.1370/afm.1139]

35 **Wang W**, Bian Q, Zhao Y, Li X, Wang W, Du J, Zhang G, Zhou Q, Zhao M. Reliability and validity of the Chinese version of the Patient Health Questionnaire (PHQ-9) in the general population. *Gen Hosp Psychiatry* 2014; **36**: 539-544 [PMID: 25023953 DOI: 10.1016/j.genhosppsych.2014.05.021]

36 **Fann JR**, Bombardier CH, Dikmen S, Esselman P, Warms CA, Pelzer E, Rau H, Temkin N. Validity of the Patient Health Questionnaire-9 in assessing depression following traumatic brain injury. *J Head Trauma Rehabil* 2005; **20**: 501-511 [PMID: 16304487 DOI: 10.1097/00001199-200511000-00003]

37 **Bombardier CH**, Richards JS, Krause JS, Tulsky D, Tate DG. Symptoms of major depression in people with spinal cord injury: implications for screening. *Arch Phys Med Rehabil* 2004; **85**: 1749-1756 [PMID: 15520969 DOI: 10.1016/j.apmr.2004.07.348]

38 **Williams LS**, Brizendine EJ, Plue L, Bakas T, Tu W, Hendrie H, Kroenke K. Performance of the PHQ-9 as a screening tool for depression after stroke. *Stroke* 2005; **36**: 635-638 [PMID: 15677576 DOI: 10.1161/01.STR.0000155688.18207.33]

39 **Akena D**, Joska J, Obuku EA, Stein DJ. Sensitivity and specificity of clinician administered screening instruments in detecting depression among HIV-positive individuals in Uganda. *AIDS Care* 2013; **25**: 1245-1252 [PMID: 23398282 DOI: 10.1080/09540121.2013.764385]

40 **Pakistan Bureau of statistics**. Population Census. [Cited 10 September 2021]. Available from: http://www.pbs.gov.pk/content/population-census

41 **Pinto-Meza A**, Serrano-Blanco A, Peñarrubia MT, Blanco E, Haro JM. Assessing depression in primary care with the PHQ-9: can it be carried out over the telephone? *J Gen Intern Med* 2005; **20**: 738-742 [PMID: 16050884 DOI: 10.1111/j.1525-1497.2005.0144.x]

42 **Kroenke K**, Spitzer RL, Williams JB, Löwe B. The Patient Health Questionnaire Somatic, Anxiety, and Depressive Symptom Scales: a systematic review. *Gen Hosp Psychiatry* 2010; **32**: 345-359 [PMID: 20633738 DOI: 10.1016/j.genhosppsych.2010.03.006]

43 **Haddad M**, Walters P, Phillips R, Tsakok J, Williams P, Mann A, Tylee A. Detecting depression in patients with coronary heart disease: a diagnostic evaluation of the PHQ-9 and HADS-D in primary care, findings from the UPBEAT-UK study. *PLoS One* 2013; **8**: e78493 [PMID: 24130903 DOI: 10.1371/journal.pone.0078493]

44 **Urtasun M**, Daray FM, Teti GL, Coppolillo F, Herlax G, Saba G, Rubinstein A, Araya R, Irazola V. Validation and calibration of the patient health questionnaire (PHQ-9) in Argentina. *BMC Psychiatry* 2019; **19**: 291 [PMID: 31533674 DOI: 10.1186/s12888-019-2262-9]

45 **Dadfar M**, Kalibatseva Z, Lester D. Reliability and validity of the Farsi version of the Patient Health Questionnaire-9 (PHQ-9) with Iranian psychiatric outpatients. *Trends Psychiatry Psychother* 2018; **40**: 144-151 [PMID: 29995159 DOI: 10.1590/2237-6089-2017-0116]

46 **Kendrick T**, Dowrick C, McBride A, Howe A, Clarke P, Maisey S, Moore M, Smith PW. Management of depression in UK general practice in relation to scores on depression severity questionnaires: analysis of medical record data. *BMJ* 2009; **338**: b750 [PMID: 19299475 DOI: 10.1136/bmj.b750]

47 **Nolan CP**, O'Donnell PJM, Desderius BM, Mzombwe M, McNairy ML, Peck RN, Kingery JR. Depression screening in HIV-positive Tanzanian adults: comparing the PHQ-2, PHQ-9 and WHO-5 questionnaires. *Glob Ment Health (Camb)* 2018; **5**: e38 [PMID: 30637111 DOI: 10.1017/gmh.2018.31]

48 **Yu X**, Stewart SM, Wong PT, Lam TH. Screening for depression with the Patient Health Questionnaire-2 (PHQ-2) among the general population in Hong Kong. *J Affect Disord* 2011; **134**: 444-447 [PMID: 21665288 DOI: 10.1016/j.jad.2011.05.007]

49 **Yeung A**, Fung F, Yu SC, Vorono S, Ly M, Wu S, Fava M. Validation of the Patient Health Questionnaire-9 for depression screening among Chinese Americans. *Compr Psychiatry* 2008; **49**: 211-217 [PMID: 18243896 DOI: 10.1016/j.comppsych.2006.06.002]

50 **Suzuki K**, Kumei S, Ohhira M, Nozu T, Okumura T. Screening for major depressive disorder with the Patient Health Questionnaire (PHQ-9 and PHQ-2) in an outpatient clinic staffed by primary care physicians in Japan: a case control study. *PLoS One* 2015; **10**: e0119147 [PMID: 25789476 DOI: 10.1371/journal.pone.0119147]

51 **Rice DB**, Thombs BD. Risk of Bias from Inclusion of Currently Diagnosed or Treated Patients in Studies of Depression Screening Tool Accuracy: A Cross-Sectional Analysis of Recently Published Primary Studies and Meta-Analyses. *PLoS One* 2016; **11**: e0150067 [PMID: 26919313 DOI: 10.1371/journal.pone.0150067]

52 **Streiner DL,** Norman GR. Scaling responses. Health Measurement Scales: a practical guide to their development and use. 2nd ed. Oxford: Oxford University Press; 1995

53 **Huang FY**, Chung H, Kroenke K, Delucchi KL, Spitzer RL. Using the Patient Health Questionnaire-9 to measure depression among racially and ethnically diverse primary care patients. *J Gen Intern Med* 2006; **21**: 547-552 [PMID: 16808734 DOI: 10.1111/j.1525-1497.2006.00409.x]

54 **Lee PW**, Schulberg HC, Raue PJ, Kroenke K. Concordance between the PHQ-9 and the HSCL-20 in depressed primary care patients. *J Affect Disord* 2007; **99**: 139-145 [PMID: 17049999 DOI: 10.1016/j.jad.2006.09.002]

55 **Williams KG**, Sanderson M, Jette N, Patten SB. Validity of the Patient Health Questionnaire-9 in neurologic populations. *Neurol Clin Pract* 2020; **10**: 190-198 [PMID: 32642320 DOI: 10.1212/CPJ.0000000000000748]

56 **Monahan PO**, Shacham E, Reece M, Kroenke K, Ong'or WO, Omollo O, Yebei VN, Ojwang C. Validity/reliability of PHQ-9 and PHQ-2 depression scales among adults living with HIV/AIDS in western Kenya. *J Gen Intern Med* 2009; **24**: 189-197 [PMID: 19031037 DOI: 10.1007/s11606-008-0846-z]

57 **Cholera R**, Gaynes BN, Pence BW, Bassett J, Qangule N, Macphail C, Bernhardt S, Pettifor A, Miller WC. Validity of the Patient Health Questionnaire-9 to screen for depression in a high-HIV burden primary healthcare clinic in Johannesburg, South Africa. *J Affect Disord* 2014; **167**: 160-166 [PMID: 24972364 DOI: 10.1016/j.jad.2014.06.003]

58 **Chibanda D**, Verhey R, Gibson LJ, Munetsi E, Machando D, Rusakaniko S, Munjoma R, Araya R, Weiss HA, Abas M. Validation of screening tools for depression and anxiety disorders in a primary care population with high HIV prevalence in Zimbabwe. *J Affect Disord* 2016; **198**: 50-55 [PMID: 27011359 DOI: 10.1016/j.jad.2016.03.006]

**Footnotes**

**Institutional review board statement:** The study was reviewed and approved by the Ethics Committee of Jinnah hospital Lahore, Pakistan.

**Informed consent statement:** Informed consent was obtained from all patients for being included in the study.

**Conflict-of-interest statement:** All the authors have no conflicts of interest.

**Data sharing statement:** Participants gave informed consent for data sharing and the presented data are anonymized and the risk of identification is low.

**STROBE statement:** The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** March 20, 2022

**First decision:** April 18, 2022

**Article in press:** August 26, 2022

**Specialty type:** Psychiatry

**Country/Territory of origin:** Pakistan

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0


Grade C (Good): C, C

Grade D (Fair): 0

Grade E (Poor): E

**P-Reviewer:** Diaz-Batanero C, Spain; Masaru T, Hungary **S-Editor:** Liu JH **L-Editor:** A **P-Editor:** Liu JH

**Figure Legends**



**Figure 1 Receiver operating characteristic curve of Patient Health Questionnaire-2 for depression screening.** AUC: Area under the curve.

**Table 1 Socio demographic characteristics of human immunodeficiency virus positive patients (*n* = 158)**

|  |  |  |  |
| --- | --- | --- | --- |
| **Variables** | **Non-depression, *n* (%)** | **Depression, *n* (%)** | ***P* value** |
|  | **104 (65.8)** | **54 (34.1)** |  |
| **Age (yr)** | | | |
| mean ± SD | 30.42 ± 7.11 | 43.91 ± 5.133 | **0.001a** |
| **Gender** |  | | |
| Male | 89 (56.3) | 46 (29.1) | 0.947 |
| Female | 15 (9.5) | 8 (5.1) |  |
| **Education** | | | |
| No education | 62 (39.2) | 27 (17.1) | 0.377 |
| Up to primary school | 11 (7.0) | 6 (3.8) |  |
| Up to secondary school | 23 (14.6) | 14 (8.9) |  |
| Up to college | 4 (2.5) | 6 (3.8) |  |
| Up to University | 4 (2.5) | 1 (0.6) |  |
| **Marital status** | | | |
| Married | 51 (32.3) | 42 (26.6) | **0.001a** |
| Unmarried | 47 (29.7) | 4 (2.5) |  |
| Separated | 1 (0.6) | 5 (3.2) |  |
| Divorced | 4 (2.5) | 2 (1.3) |  |
| Widowed | 1 (0.6) | 0 (0.6) |  |
| **Monthly family income** | | | |
| Less than 20000 Rs | 66 (41.8) | 17 (10.8) | **0.001a** |
| Between Rs. 20000-30000 | 29 (18.4) | 25 (15.8) |  |
| More than Rs. 30000 | 9 (5.7) | 12 (7.6) |  |
| **Residential status** | | | |
| Rural | 36 (22.8) | 25 (15.8) | 0.153 |
| Urban | 68 (43.0) | 29 (18.4) |  |
| **Religion** | | | |
| Muslim | 101 (63.9) | 50 (31.6) | 0.190 |
| Non-Muslim | 3 (1.9) | 4 (2.5) |  |

a*P* value < 0.05.

**Table 2 Item analysis of patient health questionnaire-9**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **PHQ-9** | **Mean** | **SD** | **Item-total correlation** | **α if item deleted** |
| Little interest or pleasure in doing things | 1.06 | 1.005 | 0.432 | 0.738 |
| Feeling down, depressed, or hopeless | 1.01 | 1.003 | 0.301 | 0.761 |
| Trouble falling or staying asleep, or sleeping too much | 1.06 | 0.975 | 0.422 | 0.739 |
| Feeling tired or having little energy | 1.27 | 0.803 | 0.414 | 0.740 |
| Poor appetite or overeating | 1.15 | 0.797 | 0.460 | 0.733 |
| Feeling bad about yourself — or that you are a failure or have let yourself or your family down | 1.07 | 0.775 | 0.518 | 0.726 |
| Trouble concentrating on things, such as reading a newspaper or watching television | 1.13 | 0.799 | 0.381 | 0.745 |
| Moving or speaking so slowly that other people could have noticed? Or the opposite — being so fidgety or restless that you have been moving around a lot more than usual | 1.11 | 0.834 | 0.496 | 0.728 |
| Thoughts that you would be better off dead or of hurting yourself in some way | 1.06 | 0.926 | 0.559 | 0.716 |

PHQ-9: Patient health questionnaire-9.

**Table 3 Sensitivity, specificity, predictive values, at various cut-off scores of the patient health questionnaire-2**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **PHQ-2 score** | **Sensitivity (95%CI)** | **Speciﬁcity (95%CI)** | **PPV (95%CI)** | **NPV (95%CI)** | **Youden’s index** |
| ≥ 1 | 100.00 (93.4-100.0) | 59.62 (49.5-69.1) | 21.6 (17.9-25.8) | 100.0 (93.4-100.) | **59.62** |
| ≥ 2 | 96.30 (87.3-99.5) | 96.15 (90.4-98.9) | 73.6 (51.5-87.9) | 99.6 (98.4-99.9) | **92.45** |
| ≥ 3 | 66.67 (52.5-78.9) | 100.(96.5-100.0) | 100.0 (96.5-100.0) | 96.4(94.9-97.5) | **66.67** |
| ≥ 4 | 31.48 (96.5-100.0) | 100.0 (96.5-100.0) | 100.0 (96.5-100.0) | 92.9 (91.6-94.0) | **31.48** |
| ≥ 5 | 14.81 (6.6-27.1) | 100.0 (96.5-100.0) | 100.0 (96.5-100.0) | 91.4 (90.4-92.2) | **14.81** |

PHQ-2: Patient health questionnaire-2; PPV: Positive predictive value; NPV: Negative predictive value.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +19253991568

**Email:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2022 Baishideng Publishing Group Inc. All rights reserved.**